Eiger BioPharmaceuticals, Inc. - FORM 10-Q - EX-10.1 - August 11, 2015

Attached files

file filename
EX-10.4 - EX-10.4 - Eiger BioPharmaceuticals, Inc.d937948dex104.htm
EX-10.3 - EX-10.3 - Eiger BioPharmaceuticals, Inc.d937948dex103.htm
EX-10.5 - EX-10.5 - Eiger BioPharmaceuticals, Inc.d937948dex105.htm
EX-10.2 - EX-10.2 - Eiger BioPharmaceuticals, Inc.d937948dex102.htm
EX-32.2 - EX-32.2 - Eiger BioPharmaceuticals, Inc.d937948dex322.htm
EX-31.1 - EX-31.1 - Eiger BioPharmaceuticals, Inc.d937948dex311.htm
EX-32.1 - EX-32.1 - Eiger BioPharmaceuticals, Inc.d937948dex321.htm
EX-31.2 - EX-31.2 - Eiger BioPharmaceuticals, Inc.d937948dex312.htm
EX-10.9 - EX-10.9 - Eiger BioPharmaceuticals, Inc.d937948dex109.htm
EX-10.8 - EX-10.8 - Eiger BioPharmaceuticals, Inc.d937948dex108.htm
EX-10.7 - EX-10.7 - Eiger BioPharmaceuticals, Inc.d937948dex107.htm
EX-10.6 - EX-10.6 - Eiger BioPharmaceuticals, Inc.d937948dex106.htm
EX-10.11 - EX-10.11 - Eiger BioPharmaceuticals, Inc.d937948dex1011.htm
EX-10.10 - EX-10.10 - Eiger BioPharmaceuticals, Inc.d937948dex1010.htm
10-Q - 10-Q - Eiger BioPharmaceuticals, Inc.d937948d10q.htm

Exhibit 10.1

CELLADON CORPORATION

SUMMARY OF RETENTION PROGRAM

Adopted April 26, 2015

Amended on May 13, 2015

Pursuant to Celladon Corporation’s retention program, the executives officers and former executive officers listed below will be eligible to receive, or have received, a lump sum retention payment equal to 50% of his or her base salary upon such individual remaining employed by Celladon until December 31, 2015, or such individual’s earlier termination without cause prior to such date:

 

Executive Officer

    Retention Payment
Current:     

Andrew Jackson

      $ 110,000  

Rebecque Laba

      $ 141,934  

Elizabeth Reed

      $ 140,250  

Fred Wiklund

      $ 125,712  
Former:     

Jeff Rudy*

      $ 143,312  

Ryan Takeya*

      $ 120,328  

 

*  Terminated without cause.

     

Eiger BioPharmaceuticals, Inc. Reports